natgillin/translations-raw huggingface dataset:
After a tenfold overdose in both dog and cat the following clinical signs have been observed: 
Poslije predoziranja desetorostrukom dozom i u pasa i u mačaka zabilježeni su sljedeći klinički simptomi:
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 
14. DATUM KADA JE UPUTA O PROIZVODU ZADNJI PUT ODOBRENA
Dispose of waste material in accordance with local requirements 
Odlaganje otpadnih materijala u skladu s lokalnim propisima
Shelf life after reconstitution according to directions: use immediately. 
Rok valjanosti poslije rekonstitucije prema uputi: primijeniti odmah.
Store and transport refrigerated. 
Čuvati i prevoziti na hladnom mjestu.
Pregnancy and lactation 
Graviditet i laktacija:
Solvent: colourless liquid. 
Otapalo: bezbojna tekućina.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
OSNOVNI PODACI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKIRANJA
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 
DOZIRANJE ZA SVAKU CILJNU VRSTU ŽIVOTINJA, NAČIN I PUT(EVI)
The import, possession, sale, supply and/or use of this veterinary medicinal product may be prohibited in a Member State on the whole or part of its territory, see package leaflet for further information. 
Uvoz, posjedovanje, prodaja, opskrba i/ili primjena ovog veterinarsko-medicinskog proizvoda je ili može biti zabranjena u određenim državama članicama na cijelom ili na dijelu njihovog teritorija, za daljnje informacije vidi uputu o proizvodu.
• mild lethargy and drowsiness 
• blaga letargija i dremljivost
The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections. 
Mogućnost pojave autoimunih poremećaja u tretiranih životinja ne može se isključiti i treba s njom računati prilikom procjene rizika kod FeLV/FIV infekcija.
• slight sinus tachycardia. 
• blaža sinusna tahikardija.
Read the package leaflet before use. 
Pročitati uputu o proizvodu prije primjene.
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product. 
Ne miješati s bilo kojim drugim veterinarskim medicinskim proizvodom, osim otapalom priloženim za primjenu s proizvodom.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nehotičnog samo injiciranja, odmah potražiti pomoć liječnika i pokazati mu uputu o proizvodu ili etiketu.
Dogs: Intravenous route Cats: Subcutaneous route 
Psi: intravenozna primjena Mačke: subkutana primjena
Overdose (symptoms, emergency procedures, antidotes) 
Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports) 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e) ) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja)
Three separate 5-day treatments must be performed at day 0, day 14 and day 60. 
Potrebna su tri odvojena 5-dnevna tretmana, primjenjena nultog, četrnaestog i šezdesetog dana.
Cat vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated as both FeLV and FIV infections are known to be immunosuppressive. 
Cijepljenje mačaka tijekom i nakon tretmana VIRBAGEN-om OMEGA je kontraindicirano jer su i FeLV i FIV infekcije poznate kao imunosupresivne.
The import, sale, supply and/or use of VIRBAGEN OMEGA is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy. 
Uvoz, prodaja, opskrba i primjena VIRBAGEN OMEGA, je ili može biti zabranjena u određenoj državi članici u cijelosti ili samo na djelu njezinog teritorija, u skladu s nacionalnim zakonodavstvom.
Dispose of waste material in accordance with local requirements. 
Odlaganje otpadnih materijala u skladu s lokalnim propisima.
Slight and transient clinical signs such as hyperthermia (3-6 hours after injection) lethargy and digestive signs ( vomiting and soft faeces to mild diarrhoea, in cats only) were commonly observed in safety studies. 
Blaži i privremeni klinički znakovi kao što su hipertermija (36 sati nakon injekcije) letargija i probavni znakovi (povraćanje i mekši feces do blagog prolijeva samo kod mačaka.) zabilježeni su u ispitivanjima neškodljivosti.
A slight decrease in white blood cells, platelets and red blood cells, and rise in the concentration of alanine aminotransferase were observed very commonly in safety studies. 
Dodatno je moguće zabilježiti blaži pad leukocita, trombocita i eritrocita, te porast koncentracije alanin aminotransferaze što je jako uobičajeno u ispitivanjima neškodljivosti.
1055 Budapest Magyarország Teл: +36703387177 
VIRBAC Hungary KFT Szent Istvàn krt.11.II/21. 1055 Budapest Magyarország Teл: +36703387177
Store in the original carton. 
Držati u originalnom pakovanju.
Cats. 
Mačke
In some cases, during treatment, the following transitory clinical signs may be observed in dogs and cats: 
U nekim slučajevima tijekom tretmana pasa i mačaka mogu se primijetiti sljedeći prolazni klinički simptomi:
Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit. 
Psi i mačke: Radi postizanja kliničkog učinka važno je točno se pridržavati preporučenog doziranja.
The product should be used with the accompanying solvent only. 
Proizvod se koristi samo s pripadajućim otapalom.
The product should be used immediately after reconstitution. 
Proizvod primijeniti odmah nakon rekonstitucije.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE 
13. RIJEČI “SAMO ZA PRIMJENU NA ŽIVOTINJAMA” I UVJETI ILI OGRANIČENJA
Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. 
Smanjenje smrtnosti i kliničkih simptoma parvoviroze (crijevni oblik) kod pasa starijih od jednog mjeseca.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE 
UVJETI ILI OGRANIČENJA ODOBRENJA ZA PUŠTANJE U PROMET S OBZIROM NA SIGURNU I DJELOTVORNU UPOTREBU
5 MU 
5 MJ
Each dose of 1 ml contains: 
Svaka doza od 1 ml sadrži:
4.5 Special precautions for use Special precautions for use in animals 
4.5 Posebne mjere opreza prilikom primjene Posebne mjere opreza prilikom primjene na životinjama
Slight and transient clinical signs such as hyperthermia (3-6 hours after injection) lethargy and digestive signs (vomiting and soft faeces to mild diarrhoea, in cats only. ) 
Lagani i kratkotrajni klinički znakoci kao što je hipertermija (36 sati nakon primjene) letargija i probavni znakovi (povraćanje i mekana stolica do laganog proljeva kod mačaka).
In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse. 
mekši feces, anoreksija, manji unos vode ili kolaps.
Omega interferon of feline origin, produced by genetic engineering, is a type Ι interferon closely related to alpha interferon. 
5.1 Farmakodinamička svojstva Omega interferon mačjeg podrijetla dobiven genetskim inženjeringom je interferon tipa
Each dose of 1ml contains: 
Svaka doza od 1 mL sadrži:
EXP {month/year} The product should be used immediately after reconstitution. 
EXP {mjesec/godina} Proizvod primijeniti odmah nakon rekonstitucije.
10 MU 
10 MJ
For the 10MU presentation: 
Pakovanje od 10 MJ:
VIRBAGEN OMEGA 10 MU for dogs and cats 
VIRBAGEN OMEGA 10 MJ za pse i mačke
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 
I SAŽETAK OPISA SVOJSTAVA PROIZVODA
VIRBAGEN OMEGA 5 MU for dogs and cats VIRBAGEN OMEGA 10 MU for dogs and cats 
VIRBAGEN OMEGA 5 MJ za pse i mačke VIRBAGEN OMEGA 10 MJ za pse i mačke
Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of VIRBAGEN OMEGA. 
Mačke: u slučaju ponovljenih tretmana kroničnih bolesti kod kojih su prisutni hepatitis, te slabost srca i bubrega postojeća bolest mora biti praćena prije nego se pristupi aplikaciji VIRBAGEN OMEGA.
In a field study conducted, it was observed that there was: - a reduction of clinical signs during the symptomatic phase (4 months) - a reduction of mortality : 
- smanjenja kliničkih znakova tijekom simptomatske faze (4 mjeseca)
No interaction has been observed during the treatment with VIRBAGEN OMEGA together with antibiotics, solution for rehydration, vitamins and non steroidal anti-inflammatory agents. 
VIRBAGEN-om OMEGA nisu zabilježene interakcije sa antibioticima, rehidracijskim otopinama,
VIRBAGEN OMEGA 5 MU for dogs and cats 
VIRBAGEN OMEGA 5 MJ za pse i mačke
Dogs: Vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated, until the dog appears to have recovered. 
Psi: cijepljenje tijekom i nakon tretmana sa VIRBAGEN OMEGA je kontraindicirano sve dok se pas ne oporavi.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE 
UVJETI ILI OGRANIČENJA ODOBRENJA ZA STAVLJANJE U PROMET U POGLEDU OPSKRBE I PRIMJENE
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKI DJELATNE(IH) TVAR(I) I VLASNICI ODOBRENJA
Dogs. 
Psi
Batch {number} 
Serija{broj}
Cats: as vaccination is contra-indicated in the symptomatic phase of FeLV/FIV infections, the effect of VIRBAGEN OMEGA on cat vaccination has not been evaluated. 
Mačke: Pošto je cijepljenje kontraindicirano u simptomatskoj fazi infekcije sa FeLV/FIV učinak VIRBAGEN OMEGA na cijepljenje mačaka nije istraživan.
Marketing authorisation holder and manufacturer responsible for batch release 
Nositelj odobrenja i proizvođač odgovoran za puštanje proizvoda u prodaju
VIRBAGEN OMEGA Solvent for suspension for injection 
Otapalo za suspenziju za injekciju
EXP: {month/year} Once reconstituted use immediately. 
EXP {mjesec/godina} Poslije rekonstitucije primijeniti odmah.
Solvent: Type I glass vial of 1 ml of solvent closed with butyl elastomer rubber stopper. 
Staklena bočica tipa I, od 1 ml zatvorena gumenim čepom od gumenog butilelastomera
The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon. 
Liofilizirana frakcija mora biti rekonstituirana s 1 ml specifičnog otapala ovisno o tome da li prozirna i bezbojna suspenzija sadrži 5 MJ ili 10 MJ rekombiniranog interferona.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT 
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE PROIZVODNE
STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains: 
SASTAV DJELATNIH TVARI Svaka doza od 1 ml sadrži: Djelatna tvar:
Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9 weeks. 
Liječenje mačaka inficiranih s FeLV i/ili FIV u neterminalnim kliničkim stadijima starijih od 9 tjedana.
Dogs: The dose is 2.5 MU/kg bodyweight. 
Psi: doza je 2,5 MJ/kg tjelesne mase.
Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested. 
Djelotvornost proizvoda kod mačaka s tumoroznim oblikom infekcije FeLV ili mačaka zaraženih s
Isotonic sodium chloride solution 
Izotonična otopina natrijevog klorida
Cats: Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9 weeks. 
Mačke: Liječenje mačaka zaraženih s FeLV i/ili FIV, u neterminalnim kliničkim stadijima starijih od 9 tjedana.
The dose is 2.5 MU/kg bodyweight. 
Doza je 2,5 MJ/kg tjelesne mase
Cats: The dose is 1 MU/kg bodyweight. 
Mačke: doza je 1 MJ/kg tjelesne mase.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KARTONSKA KUTIJA
Cats: The reconstituted product should be injected subcutaneously once daily for 5 consecutive days. 
Mačke: rekonstituirani proizvod treba aplicirati potkožno jedan puta na dan tijekom 5 uzastopnih dana.
Box containing 2 vials of lyophilisate and 2 vials with 1 ml of solvent. 
Kutija s 2 bočice liofilizata i 2 bočice s 1 ml otapala.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 
IZJAVA O DJELATNIM TVARIMA I DRUGIM SASTOJCIMA
Dogs: The reconstituted product should be injected intravenously once daily for 3 consecutive days. 
Psi: rekonstituirani proizvod treba aplicirati intravenozno jedan puta na dan tijekom tri uzastopna dana.
Once reconstituted use immediately. 
Poslije rekonstitucije odmah primijeniti.
The dose is 1 MU/kg bodyweight. 
Doza je 1 MJ/kg tjelesne mase.
Box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent. 
Kutija s 5 bočica liofilizata i 5 bočica s 1 ml otapala.
The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a suspension containing 5 MU of recombinant interferon. 
NAČIN I PUT(EVI) PRIMJENE Liofilizirana frakcija mora biti rekonstituirana sa 1 ml specifičnog otapala da bi se dobila suspenzija koja sadrži 5 MJ rekombiniranog interferona.
The reconstituted product should be injected subcutaneously once daily for 5 consecutive days. 
Rekonstituirani proizvod treba aplicirati potkožno jednom dnevno, tijekom 5 uzastopnih dana.
For the 5MU presentation: Cardboard box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent 
Pakovanje od 5MJ: Kartonska kutija s 5 bočica liofilizata, i 5 bočica s 1 mL otapala.
The reconstituted product should be injected intravenously once daily for 3 consecutive days. 
Rekonstituirani proizvod treba aplicirati intravenozno jednom dnevno tijekom 3 uzastopna dana.
Tel: +33-(0)4 92 08 73 00 
France Tel: + 33-(0)4 92 08 73 00
Lyophilisate: white pellet Solvent: colourless liquid 
Liofilizat: bijele pelete
The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon. 
NAČIN I PUT(EVI) PRIMJENE Liofilizirana frakcija mora biti rekonstituirana sa 1 ml specifičnog otapala da bi se dobila suspenzija koja sadrži 10 MJ rekombiniranog interferona.
10 MU presentation: Recombinant Omega interferon of feline origin 
Jačina 10 MJ: Rekombinirani omega interferon mačjeg podrijetla 10 MJ*
Recombinant Omega interferon of feline origin 10 MU* *MU : Million Units 
Rekombinirani omega interferon mačjeg podrijetla 10 MJ*
Recombinant Omega interferon of feline origin 5 MU* 10 MU presentation: 
Rekombinirani omega interferon mačjeg podrijetla 5 MJ*
Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent. 
Kartonska kutija s 1 bočicom liofilizata i 1 bočicom s 1 ml otapala.
Cats: as vaccination is contra-indicated in symptomatic phase of FeLV/FIV infections, effect of VIRBAGEN OMEGA on cat vaccination has not been evaluated. 
Mačke: pošto je cijepljenje kontraindicirano u simptomatskoj fazi infekcije s FeLV/FIV učinak
This summary was last updated in 08-2016. 
Sažetak je posljednji put ažuriran u 08.2016.
The full EPAR for IDflu can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek IDflu nalazi se na internetskim stranicama Agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
IDflu contains 15 micrograms of each of three different strains (varieties) of influenza virus (an H1N1 subtype, A/California/7/2009, NYMC X-179A; an H3N2 subtype, A/Hong Kong/4801/2014, NYMC X-263B; and a type B, B/Brisbane/60/2008, wild type). 
IDflu sadrži 15 mikrograma svakog od tri soja (vrste) virusa gripe (podvrsta H1N1, A/California/7/2009, NYMC X-179A, podvrsta H3N2, A/Hong Kong/4801/2014, NYMC X-263B i tip B, B/Brisbane/60/2008, divlji soj).
What measures are being taken to ensure the safe and effective use of IDflu? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka IDflu?
influenza vaccine (split virion, inactivated) 
Cjepivo protiv influence (fragmentirani virion, inaktivirano)
Other information about IDflu 
Ostale informacije o lijeku IDflu
For more information about treatment with IDflu, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom IDflu pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
This is a summary of the European public assessment report (EPAR) for IDflu. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek IDflu.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains. 
Ubuduće će imunosni sustav biti u stanju brže stvarati protutijela nakon izloženosti bilo kojem od ovih sojeva virusa.
The antibodies will then help to protect against the disease caused by these strains of flu virus. 
Protutijela zatim pomažu u zaštiti od bolesti uzrokovane tim sojevima virusa gripe.
The other two studies looked at use of a lower strength in people under the age of 60. 
U druga su dva ispitivanja proučavane primjene manjih doza u ljudi mlađih od 60 godina.
Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season. 
Svake godine Svjetska zdravstvena organizacija (SZO) preporučuje koji se sojevi gripe moraju uključiti u cjepiva za nadolazeću sezonu gripe.
Fragments of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in IDflu before the 
Fragmenti sojeva virusa za koje se očekuje da će prouzročiti gripu u nadolazećoj sezoni u skladu s preporukama SZO-a za sjevernu hemisferu kao i preporukama Europske unije (EU) moraju biti dodani cjepivu IDflu prije korištenja.
The most common side effects with IDflu (seen in more than 1 patient in 10) are headache, muscle pain and local reactions at the site of the vaccination (redness, swelling, hardening of the skin, pain and itching). 
Najčešće nuspojave cjepiva IDflu (zabilježene u više od 1 na 10 osoba) su glavobolja, bol u mišićima i lokalne reakcije na mjestu cijepljenja (crvenilo, oteklina, otvrdnuće kože, bol i svrbež).
The vaccine contains fragments of influenza (flu) viruses that have been inactivated (treated to prevent them causing infection). 
Cjepivo sadrži fragmente virusa influence (gripe) koji su inaktivirani (obrađeni tako da sprečavaju nastanak infekcije).
When a person is given the vaccine, the immune system recognises the virus fragments as ‘foreign' and makes antibodies against them. 
Nakon što osoba primi cjepivo, imunosni sustav prepoznaje fragmente virusa kao „strane” te protiv njih proizvodi protutijela.
The immunogenicity and safety of subsequent formulations of the vaccine have also been examined in 
Imunogenost i sigurnost naknadnih formulacija cjepiva također su proučavane u ispitivanjima.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka IDflu.
IDflu is a vaccine. 
IDflu je cjepivo.
IDflu is used to vaccinate adults aged 60 years and over against flu, especially those who are at an increased risk of developing complications from the disease. 
IDflu se koristi za cijepljenje osoba od 60 godina i starijih protiv gripe, posebice onih koji su izloženi riziku od razvijanja komplikacija bolesti.
IDflu contains fragments from three different strains of flu virus. 
IDflu sadrži fragmente iz tri različita soja virusa gripe.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of IDflu have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka IDflu nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
IDflu is given as one ‘intradermal' injection into the upper layer of the skin, using a special micro-injection system. 
IDflu se primjenjuje „intradermalnom” injekcijom u gornji sloj kože uz pomoć posebnog sustava mikro-injekcije.
The shoulder is the recommended site of injection. 
Preporučeno mjesto primjene injekcije je područje ramena.
IDflu must not be used in people who are hypersensitive (allergic) to the active substances, to any of the other ingredients, or to any component that may be present in very small amounts such as egg (ovalbumin, chicken proteins), neomycin, formaldehyde or octoxinol 9. 
IDflu se ne smije primjenjivati u osoba koje se preosjetljive (alergične) na djelatne tvari ili na bilo koji drugi sastojak, odnosno bilo koju komponentu koja može biti prisutna u vrlo malim količinama poput jaja (ovalbumin, pileći protein), neomicina, formaldehida ili octoksinola 9. Osobe koje imaju vrućicu ili akutnu (kratkoročnu) upalu ne smiju primiti cjepivo sve dok se ne oporave.
The vaccine can only be obtained with a prescription. 
Cjepivo se izdaje samo na liječnički recept.
IDflu is a vaccine, which is available as a suspension for injection in a pre-filled syringe. 
IDflu je cjepivo koje je dostupno kao suspenzija za injekciju u prethodno napunjenoj štrcaljki.
What is the risk associated with IDflu? 
Koji su rizici povezani s lijekom IDflu?
In people aged 60 years and over, the 15-microgram strength provided as good a level of protection as the comparator vaccines. 
U osoba u dobi od 60 godina i starijih, cjepivo jačine od 15 mikrograma potaklo je podjednako dobru razinu zaštite kao i usporedna cjepiva.
In one study in people aged 60 years and over, IDflu was compared with a flu vaccine containing an adjuvant (a compound added to enhance the immune response). 
U jednom ispitivanju u osoba u dobi od 60 godina i starijih IDflu je uspoređen s cjepivom protiv gripe koje sadrži adjuvans (spoj koji se dodaje za pojačanje imunosnog odgovora).
The CHMP decided that IDflu's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi od lijeka IDflu nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
Three studies looked at people aged 60 years and over, who were vaccinated with the 15-microgram strength. 
Tri su ispitivanja obuhvatila osobe u dobi od 60 godina i starije koje su cijepljene cjepivom jačine 15 mikrograma.
The ability of IDflu to trigger the production of antibodies (immunogenicity) was first assessed in five main studies involving almost 9,000 people. 
Sposobnost lijeka IDflu da potakne stvaranje protutijela (imunogenost) ocijenjena je u pet glavnih ispitivanja koja su obuhvatila nešto manje od 9 000 bolesnika.
In the five original studies, both IDflu and the comparator vaccine brought about adequate levels of antibodies for protection against all three flu strains. 
U pet prvotnih ispitivanja IDflu i usporedno cjepivo doveli su do primjerene razine protutijela za zaštitu protiv sva tri soja gripe.